Quarterly report pursuant to Section 13 or 15(d)

Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)

v3.23.2
Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
6 Months Ended
Jun. 30, 2023
Deferred Royalty Obligation [Abstract]  
Schedule of Royalty Obligation transaction

The following table shows the activity of the deferred royalty obligation since transaction inception through June 30, 2023:

 

 

 

June 30,

 

 

 

2023

 

 

 

(in thousands)

 

Proceeds from the sale of future Vaxcyte royalties

 

$

140,000

 

Issuance costs

 

 

(3,792

)

Non-cash interest expense associated with the sale of future Vaxcyte royalties

 

 

442

 

Amortization of issuance costs

 

 

3

 

Deferred royalty obligation related to the sale of future Vaxcyte royalties, net

 

$

136,653